BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21036766)

  • 1. Prognostic value of IL-6 in localized prostatic cancer.
    Alcover J; Filella X; Luqué P; Molina R; Izquierdo L; Augé JM; Alcaraz A
    Anticancer Res; 2010 Oct; 30(10):4369-72. PubMed ID: 21036766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
    J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Zlotta AR; Perrotte P; Suardi N; Saad F; Karakiewicz PI
    J Clin Oncol; 2008 Mar; 26(9):1526-31. PubMed ID: 18349404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.
    Shariat SF; Andrews B; Kattan MW; Kim J; Wheeler TM; Slawin KM
    Urology; 2001 Dec; 58(6):1008-15. PubMed ID: 11744478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy.
    Lin HC; Liu CC; Kang WY; Yu CC; Wu TT; Wang JS; Wu WJ; Huang CH; Wu MT; Huang SP
    Urol Int; 2009; 83(4):463-70. PubMed ID: 19996656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
    Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
    J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
    Reeves JR; Dulude H; Panchal C; Daigneault L; Ramnani DM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6018-22. PubMed ID: 17062675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
    Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
    J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The surgical learning curve for prostate cancer control after radical prostatectomy.
    Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
    J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
    Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.